Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

The problem, Zaaijer explained, is that algorithms used in precision medicine models overwhelming are built on DNA with ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...

Cholesterol meds—taking by millions of Americans every day—often come with a lifelong prescription, adding out-of-pocket ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...